AP706A - Injectable quinolone formulations. - Google Patents
Injectable quinolone formulations. Download PDFInfo
- Publication number
- AP706A AP706A APAP/P/1996/000898A AP9600898A AP706A AP 706 A AP706 A AP 706A AP 9600898 A AP9600898 A AP 9600898A AP 706 A AP706 A AP 706A
- Authority
- AP
- ARIPO
- Prior art keywords
- solution
- formulation
- danofloxacin
- added
- pvp
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title description 81
- 238000009472 formulation Methods 0.000 title description 76
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 title description 2
- QMLVECGLEOSESV-RYUDHWBXSA-N Danofloxacin Chemical compound C([C@@H]1C[C@H]2CN1C)N2C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=CC=1N2C1CC1 QMLVECGLEOSESV-RYUDHWBXSA-N 0.000 claims abstract description 34
- 229960004385 danofloxacin Drugs 0.000 claims abstract description 33
- 239000007924 injection Substances 0.000 claims abstract description 25
- 238000002347 injection Methods 0.000 claims abstract description 25
- 239000006184 cosolvent Substances 0.000 claims abstract description 20
- 150000003752 zinc compounds Chemical class 0.000 claims abstract description 12
- 239000003186 pharmaceutical solution Substances 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- 239000000243 solution Substances 0.000 claims description 88
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 84
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 84
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 84
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 32
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 24
- 150000002681 magnesium compounds Chemical class 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 10
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 7
- 208000035143 Bacterial infection Diseases 0.000 claims description 6
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 238000010254 subcutaneous injection Methods 0.000 claims description 4
- 239000007929 subcutaneous injection Substances 0.000 claims description 4
- 230000003078 antioxidant effect Effects 0.000 claims description 3
- 241000283690 Bos taurus Species 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 229940017705 formaldehyde sulfoxylate Drugs 0.000 claims 1
- SBGKURINHGJRFN-UHFFFAOYSA-N hydroxymethanesulfinic acid Chemical compound OCS(O)=O SBGKURINHGJRFN-UHFFFAOYSA-N 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract description 4
- 229910052749 magnesium Inorganic materials 0.000 abstract description 4
- 239000011777 magnesium Substances 0.000 abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 66
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 52
- MYDXUJMODAZBGN-UHFFFAOYSA-N 6-bromo-5-methyl-2-methylsulfanyl-1h-[1,2,4]triazolo[1,5-a]pyrimidin-7-one Chemical compound CC1=C(Br)C(=O)N2NC(SC)=NC2=N1 MYDXUJMODAZBGN-UHFFFAOYSA-N 0.000 description 49
- 229960004745 danofloxacin mesylate Drugs 0.000 description 49
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 39
- 239000000395 magnesium oxide Substances 0.000 description 35
- XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 description 35
- 239000002002 slurry Substances 0.000 description 20
- 238000013019 agitation Methods 0.000 description 18
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 18
- 239000000463 material Substances 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 9
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 8
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- ISXSFOPKZQZDAO-UHFFFAOYSA-N formaldehyde;sodium Chemical compound [Na].O=C ISXSFOPKZQZDAO-UHFFFAOYSA-N 0.000 description 5
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 5
- 239000010931 gold Substances 0.000 description 5
- 229910052737 gold Inorganic materials 0.000 description 5
- -1 quinolone carboxylic acids Chemical class 0.000 description 5
- 239000004246 zinc acetate Substances 0.000 description 5
- 238000001816 cooling Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 4
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000011787 zinc oxide Substances 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 229960003666 liquefied phenol Drugs 0.000 description 2
- 150000002736 metal compounds Chemical class 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- 229940001584 sodium metabisulfite Drugs 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 206010028320 muscle necrosis Diseases 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 229940001474 sodium thiosulfate Drugs 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229940072172 tetracycline antibiotic Drugs 0.000 description 1
- 229940035024 thioglycerol Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US905295P | 1995-12-21 | 1995-12-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AP9600898A0 AP9600898A0 (en) | 1997-01-31 |
| AP706A true AP706A (en) | 1998-12-04 |
Family
ID=21735307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/1996/000898A AP706A (en) | 1995-12-21 | 1996-12-19 | Injectable quinolone formulations. |
Country Status (42)
| Country | Link |
|---|---|
| US (1) | US5811130A (cs) |
| EP (1) | EP0868183B1 (cs) |
| JP (1) | JP3416145B2 (cs) |
| KR (1) | KR100402570B1 (cs) |
| CN (1) | CN1104899C (cs) |
| AP (1) | AP706A (cs) |
| AR (1) | AR005147A1 (cs) |
| AT (1) | ATE212551T1 (cs) |
| AU (1) | AU709474B2 (cs) |
| BG (1) | BG63933B1 (cs) |
| BR (1) | BR9612230A (cs) |
| CA (1) | CA2239352C (cs) |
| CO (1) | CO4480098A1 (cs) |
| CZ (1) | CZ293747B6 (cs) |
| DE (1) | DE69618987T2 (cs) |
| DK (1) | DK0868183T3 (cs) |
| DZ (1) | DZ2146A1 (cs) |
| EG (1) | EG24071A (cs) |
| ES (1) | ES2167609T3 (cs) |
| GT (1) | GT199600098A (cs) |
| HR (1) | HRP960607B1 (cs) |
| HU (1) | HU227918B1 (cs) |
| IL (1) | IL124454A (cs) |
| IS (1) | IS2010B (cs) |
| MA (1) | MA24035A1 (cs) |
| MX (1) | MX9805026A (cs) |
| MY (1) | MY117109A (cs) |
| NO (1) | NO315734B1 (cs) |
| NZ (2) | NZ501160A (cs) |
| OA (1) | OA10697A (cs) |
| PE (1) | PE25798A1 (cs) |
| PL (1) | PL186795B1 (cs) |
| PT (1) | PT868183E (cs) |
| RS (1) | RS49523B (cs) |
| RU (1) | RU2141827C1 (cs) |
| SI (1) | SI0868183T1 (cs) |
| SK (1) | SK284412B6 (cs) |
| TN (1) | TNSN96163A1 (cs) |
| TW (1) | TW449475B (cs) |
| UA (1) | UA56151C2 (cs) |
| WO (1) | WO1997023217A1 (cs) |
| ZA (1) | ZA9610780B (cs) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ID21415A (id) * | 1997-12-05 | 1999-06-10 | Upjohn Co | Senyawa-senyawa antibiotik magnesium quinolon |
| US6017948A (en) * | 1998-10-30 | 2000-01-25 | Supergen, Inc. | Water-miscible pharmaceutical compositions |
| DE19937115A1 (de) | 1999-08-06 | 2001-02-08 | Bayer Ag | Wäßrige Arzneimittelformulierung von Moxifloxacin oder Salzen davon |
| DE19937116A1 (de) * | 1999-08-06 | 2001-02-08 | Bayer Ag | Moxifloxacin Kochsalzformulierung |
| US20030153585A1 (en) * | 2000-01-13 | 2003-08-14 | Sven-Alexander Schreder | Pharmaceutical preparations containing 2-pyrrolidone as the dissolving intermediary |
| WO2002053136A1 (fr) * | 2000-12-28 | 2002-07-11 | Takeda Chemical Industries, Ltd. | Preparations a liberation soutenue |
| JP2005535644A (ja) * | 2002-06-26 | 2005-11-24 | ファルマシア コーポレイション | 安定な非経口パレコキシブ液体製剤 |
| WO2006004028A1 (ja) * | 2004-07-02 | 2006-01-12 | Daiichi Pharmaceutical Co., Ltd. | キノロン含有医薬組成物 |
| SI2594272T1 (sl) * | 2005-05-18 | 2018-10-30 | Horizon Orphan Llc | Aerosolizirani fluorokinoloni in njih uporaba |
| US8546423B2 (en) | 2005-05-18 | 2013-10-01 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
| FR2896416B1 (fr) | 2006-01-24 | 2010-08-13 | Vetoquinol | Composition anti-infectieuse comprenant un compose de type pyrido (3,2,1-ij)-benzoxadiazine |
| TR201807714T4 (tr) * | 2006-02-10 | 2018-06-21 | Pari Pharma Gmbh | İnhalasyon tedavisine yönelik nebülize antibiyotikler. |
| US20070197548A1 (en) * | 2006-02-17 | 2007-08-23 | Murthy Yerramilli V S | Fluoroquinolone compositions |
| DE102006010643A1 (de) * | 2006-03-08 | 2007-09-13 | Bayer Healthcare Aktiengesellschaft | Arzneimittel enthaltend Fluorchinolone |
| DE102006010642A1 (de) * | 2006-03-08 | 2007-09-27 | Bayer Healthcare Aktiengesellschaft | Arzneimittelformulierungen, enthaltend Fluorchinolone |
| MX2007009796A (es) * | 2007-08-14 | 2009-02-25 | Cell Therapy And Technology S | Gel conteniendo pirfenidona. |
| MX345158B (es) | 2008-10-07 | 2017-01-18 | Raptor Pharmaceuticals Inc | Formulaciones de fluoroquinolona en aerosol para farmacocinetica mejorada. |
| DK2346509T3 (da) | 2008-10-07 | 2020-08-03 | Horizon Orphan Llc | Inhalation af levofloxacin til at reducere lungeinflammation |
| BR112012004692B8 (pt) | 2009-09-04 | 2021-05-25 | Mpex Pharmaceuticals Inc | solução que compreende levofloxacina para uso em um método para tratar a fibrose cística em um ser humano |
| MX2011007675A (es) | 2011-07-19 | 2012-07-11 | Cell Therapy And Technology S A De C V | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas. |
| MX346763B (es) | 2012-03-28 | 2017-03-31 | Cell Therapy And Tech S A De C V | Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné. |
| MX356551B (es) | 2012-08-23 | 2018-06-04 | Grupo Medifarma S A De C V Star | Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné. |
| US10617684B2 (en) | 2015-06-02 | 2020-04-14 | Kyorin Pharmaceutical Co., Ltd. | Aqueous drug |
| EP3305295A4 (en) | 2015-06-02 | 2019-02-20 | Kyorin Pharmaceutical Co., Ltd. | AQUEOUS MEDICINE |
| CA2988092A1 (en) | 2015-06-02 | 2016-12-08 | Kyorin Pharmaceutical Co., Ltd. | Aqueous liquid formulation |
| CA3053211A1 (en) * | 2017-02-13 | 2018-08-16 | Bayer Animal Health Gmbh | Liquid composition containing pradofloxacin and antioxidants |
| MX366086B (es) | 2017-08-15 | 2019-06-27 | Cell Therapy And Tech S A De C V | Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel. |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0337231A2 (de) * | 1988-04-15 | 1989-10-18 | Bayer Ag | i.m. Injektionsformen von Gyrase-Inhibitoren |
| US5084276A (en) * | 1990-01-05 | 1992-01-28 | Abbott Laboratories | Quinolone carboxylic acid compositions with polymeric additive to reduce vein irritation |
| EP0470667A1 (en) * | 1990-08-10 | 1992-02-12 | LABORATOIRES MERCK, SHARP & DOHME-CHIBRET | Composition containing a 4-quinolone derivative complexed with a divalent metal ion |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US523505A (en) * | 1894-07-24 | Island | ||
| DE3517709A1 (de) * | 1985-01-05 | 1986-07-10 | Bayer Ag | Basische zubereitungen von chinoloncarbonsaeuren |
| JPS63188626A (ja) * | 1987-01-30 | 1988-08-04 | Dainippon Pharmaceut Co Ltd | ピリドンカルボン酸の可溶化方法 |
| DK0507851T3 (da) * | 1989-12-29 | 1997-08-25 | Abbott Lab | Quinoloncarboxylsyre-matalion-syrekomplekser |
| EP0443381B2 (en) * | 1990-02-14 | 1997-10-22 | Takeda Chemical Industries, Ltd. | Effervescent composition, its production and use |
| US5082863A (en) * | 1990-08-29 | 1992-01-21 | Schering Corporation | Pharmaceutical composition of florfenicol |
| US5235054A (en) * | 1992-07-15 | 1993-08-10 | Pfizer Inc. | 3-carboxaldehyde substituted quinolines and naphthyridines |
| JPH0782141A (ja) * | 1993-09-17 | 1995-03-28 | Tanabe Seiyaku Co Ltd | 動物用注射剤 |
-
1996
- 1996-11-13 AT AT96935251T patent/ATE212551T1/de active
- 1996-11-13 CZ CZ19981930A patent/CZ293747B6/cs not_active IP Right Cessation
- 1996-11-13 UA UA98063226A patent/UA56151C2/uk unknown
- 1996-11-13 KR KR10-1998-0704719A patent/KR100402570B1/ko not_active Expired - Lifetime
- 1996-11-13 SI SI9630422T patent/SI0868183T1/xx unknown
- 1996-11-13 SK SK807-98A patent/SK284412B6/sk not_active IP Right Cessation
- 1996-11-13 ES ES96935251T patent/ES2167609T3/es not_active Expired - Lifetime
- 1996-11-13 HU HU9903726A patent/HU227918B1/hu unknown
- 1996-11-13 RU RU98111831A patent/RU2141827C1/ru active
- 1996-11-13 CN CN96199249A patent/CN1104899C/zh not_active Expired - Lifetime
- 1996-11-13 WO PCT/IB1996/001217 patent/WO1997023217A1/en active IP Right Grant
- 1996-11-13 DK DK96935251T patent/DK0868183T3/da active
- 1996-11-13 BR BR9612230A patent/BR9612230A/pt active IP Right Grant
- 1996-11-13 DE DE69618987T patent/DE69618987T2/de not_active Expired - Lifetime
- 1996-11-13 AU AU73289/96A patent/AU709474B2/en not_active Expired
- 1996-11-13 IL IL12445496A patent/IL124454A/xx not_active IP Right Cessation
- 1996-11-13 PL PL96328001A patent/PL186795B1/pl unknown
- 1996-11-13 PT PT96935251T patent/PT868183E/pt unknown
- 1996-11-13 NZ NZ501160A patent/NZ501160A/en not_active IP Right Cessation
- 1996-11-13 EP EP96935251A patent/EP0868183B1/en not_active Expired - Lifetime
- 1996-11-13 JP JP52344797A patent/JP3416145B2/ja not_active Expired - Lifetime
- 1996-11-13 NZ NZ320545A patent/NZ320545A/xx not_active IP Right Cessation
- 1996-11-13 CA CA002239352A patent/CA2239352C/en not_active Expired - Lifetime
- 1996-11-15 TW TW085114021A patent/TW449475B/zh not_active IP Right Cessation
- 1996-12-10 PE PE1996000892A patent/PE25798A1/es not_active Application Discontinuation
- 1996-12-17 EG EG113496A patent/EG24071A/xx active
- 1996-12-18 TN TNTNSN96163A patent/TNSN96163A1/fr unknown
- 1996-12-18 MA MA24427A patent/MA24035A1/fr unknown
- 1996-12-18 DZ DZ960191A patent/DZ2146A1/fr active
- 1996-12-19 AP APAP/P/1996/000898A patent/AP706A/en active
- 1996-12-19 HR HR960607A patent/HRP960607B1/xx not_active IP Right Cessation
- 1996-12-19 US US08/769,809 patent/US5811130A/en not_active Expired - Lifetime
- 1996-12-19 AR ARP960105774A patent/AR005147A1/es active IP Right Grant
- 1996-12-19 GT GT199600098A patent/GT199600098A/es unknown
- 1996-12-20 MY MYPI96005411A patent/MY117109A/en unknown
- 1996-12-20 ZA ZA9610780A patent/ZA9610780B/xx unknown
- 1996-12-20 CO CO96066993A patent/CO4480098A1/es unknown
- 1996-12-20 RS YU69096A patent/RS49523B/sr unknown
-
1998
- 1998-05-25 IS IS4755A patent/IS2010B/is unknown
- 1998-06-12 OA OA9800082A patent/OA10697A/en unknown
- 1998-06-15 BG BG102542A patent/BG63933B1/bg unknown
- 1998-06-19 NO NO19982842A patent/NO315734B1/no not_active IP Right Cessation
- 1998-06-19 MX MX9805026A patent/MX9805026A/es unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0337231A2 (de) * | 1988-04-15 | 1989-10-18 | Bayer Ag | i.m. Injektionsformen von Gyrase-Inhibitoren |
| US5084276A (en) * | 1990-01-05 | 1992-01-28 | Abbott Laboratories | Quinolone carboxylic acid compositions with polymeric additive to reduce vein irritation |
| EP0470667A1 (en) * | 1990-08-10 | 1992-02-12 | LABORATOIRES MERCK, SHARP & DOHME-CHIBRET | Composition containing a 4-quinolone derivative complexed with a divalent metal ion |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP706A (en) | Injectable quinolone formulations. | |
| CS199527B2 (en) | Manufacturing process of the steady antibiotic agent | |
| US4772460A (en) | Method of reducing the swelling or pain associated with antibiotics compositions | |
| EP1352654B1 (en) | Famotidine injections | |
| EP0769951B1 (en) | Long-acting oxytetracycline composition | |
| AU594266B2 (en) | Nicorandil-containing preparation for injection | |
| WO1996001634B1 (en) | Long-acting oxytetracycline composition | |
| US6110905A (en) | Long-acting oxytetracycline composition | |
| US4973591A (en) | Parenteral formulations of 1-diphenylmethyl-4-((2-(4-methylphenyl)-5-methyl-1H-imidazol-4-yl)methyl)piperazine | |
| US20030153581A1 (en) | Stabilized difloxacin injectable solution | |
| EP0640074B1 (en) | Salts of a quinolone-carboxylic acid | |
| US5063220A (en) | Parenteral formulations of 1-diphenylmethyl-4-((2-(4-methylphenyl)-5-methyl-1H-imidazol-4-yl)methyl)piperazine | |
| CA1217425A (en) | Oxytetracyclin-solutions | |
| WO2000072848A1 (en) | Composition comprising (±)-5-ethyldihydro-5-(1-methylbutyl)-2-thioxo 4,6(1h,5h)-pyrimidinedione dissolved in 2,5-di-o-methyl-1,4:3,6-dianhydro-d-glucitol |